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Abstract
Background: Abnormalities in Human Leukocyte Antigen (HLA) class I expression are common in
colorectal cancer. Since HLA expression is required to activate tumor antigen-specific cytotoxic T-
lymphocytes (CTL), HLA class I abnormalities represent a mechanism by which tumors circumvent
immune surveillance. Tumors with high microsatellite instability (MSI-H) are believed to face strong
selective pressure to evade CTL activity since they produce large amounts of immunogenic peptides.
Previous studies identified the prevalence of HLA class I alterations in MSI-H tumors. However, those
reports did not compare the frequency of alterations between hereditary and sporadic MSI-H tumors
neither the mechanisms that led to HLA class I alterations in each subgroup.
Methods: To characterize the HLA class I expression among sporadic MSI-H and microsatellite-stable
(MSS) tumors, and HNPCC tumors we compared immunohistochemically the expression of HLA class I,
β2-microglobulin (β2m), and Antigen Processing Machinery (APM) components in 81 right-sided sporadic
and 75 HNPCC tumors. Moreover, we investigated the genetic basis for these changes.
Results: HLA class I loss was seen more frequently in MSI-H tumors than in MSS tumors (p < 0.0001).
Distinct mechanisms were responsible for HLA class I loss in HNPCC and sporadic MSI-H tumors. Loss
of HLA class I expression was associated with β2m loss in HNPCC tumors, but was correlated with APM
component defects in sporadic MSI-H tumors (p < 0.0001). In about half of the cases, loss of expression
of HLA class I was concordant with the detection of one or more mutations in the β2m and APM
components genes.
Conclusion: HLA class I aberrations are found at varying frequencies in different colorectal tumor types
and are caused by distinct genetic mechanisms. Chiefly, sporadic and hereditary MSI-H tumors follow
different routes toward HLA class I loss of expression supporting the idea that these tumors follow
different evolutionary pathways in tumorigenesis. The resulting variation in immune escape mechanisms
may have repercussions in tumor progression and behavior.
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During cancer development, tumor cells may elicit cyto-
toxic T-lymphocyte (CTL)-mediated immune responses–
partly a consequence of accumulated gene mutations that
are translated into altered peptides [1]. Tumor cell expres-
sion of HLA class I-antigen complexes is essential for CTL
recognition of aberrant peptides and subsequent activa-
tion [2]. Consequently, alteration of HLA class I cell sur-
face expression provides an effective mechanism by which
tumors can escape immune detection [3,4]. Multiple
mechanisms have been shown to underlie defects in HLA
class I expression by tumor cells. They include mutations
in the individual HLA class I genes HLA-A, -B and -C,
located on chromosome 6p21.3) [5]; mutations in β2-
microglobulin (β2m) [6-9], molecule required for cell sur-
face expression of HLA class I antigens; and defects in
components of the HLA class I-associated antigen-
processing machinery (APM) [9-11]. The APM consists of
proteasome components delta, MB1 and Z; the immuno-
proteasome components LMP2, LMP7 and LMP10; pep-
tide transporters TAP1 and TAP2; and chaperones
Calnexin, Calreticulin, ERp57, and Tapasin. The immuno-
proteasome generates peptides mostly, although not
exclusively from endogenous proteins, TAP1 and TAP2
facilitate peptide translocation from the cytosol into the
lumen of the endoplasmic reticulum, where the peptides
are loaded onto the HLA class I molecules with the aid
from the several chaperones [12].
Chromosomal instability (CIN) and microsatellite insta-
bility (MIN) are the two major forms of genetic instability
in colorectal cancer. Combined with distinct somatic
mutation patterns and epigenetic modifications, CIN and
MIN lead to the development of sporadic colorectal can-
cer [13]. MIN sporadic tumors, which constitute approxi-
mately 15% of all colorectal cancer cases and up to 40%
of the tumors localized on the right side (preceding the
splenic flexure) of the colon [14], have a phenotype result-
ing from the epigenetic inactivation of the mismatch
repair gene hMLH1. Its inactivation destroys a cell's ability
to repair base-base mismatches and small insertions or
deletions in repetitive stretches, leading to an accumula-
tion of frameshift mutations that get translated into
abnormal peptide sequences. When these mutations are
accumulated to large extent in the cell genome the tumors
are said to possess high-microsatellite instability (MSI-H)
[15]. Hence, it is expected that genes containing microsat-
ellite sequences within their coding regions are more sus-
ceptible to somatic mutations, as seen in the TGFβ-RII
gene. TGFβ-RII's third exon contains a microsatellite
repeat of 10 adenines that is frequently targeted by
frameshift mutations in MSI-H tumors [16]. MSI-H is also
the hallmark of hereditary non-polyposis colorectal can-
cer (HNPCC), in which germline mutations of hMLH1,
hMSH2, hMSH6 and PMS2 can be found. HNPCC consti-
tutes approximately 2–4% of all CRC cases [17]. Tumors
with MSI-H are thought to be more able to stimulate a
CTL-mediated immune response due to their frequent
generation of the aberrant frameshift peptides [18]. There-
fore, these tumors are subjected to a greater selective pres-
sure which favors the outgrowth of tumor cells with the
ability to escape from recognition and destruction by host
immune system.
Various studies have identified HLA alterations in colorec-
tal cancer [19-21], including the prevalence of HLA class I
alterations in MSI-H tumors [8,22]. However, the latter
studies did not compare the frequency of alterations
between hereditary and sporadic MSI-H tumors neither
the mechanisms that led to HLA class I alterations in each
subgroup. It was suggested that MSI-H sporadic and
hereditary tumors follow parallel evolutionary pathways
during tumorigenesis in terms of both genotype and phe-
notype [23]. As far as HLA class I defects are concerned it
was never investigated whether these different tumors
present distinct escape mechanisms from the immune sys-
tem. In the present study, we compared the frequency of
defects in HLA class I expression in right-sided sporadic
(MSI-H and microsatellite-stable (MSS) sub-groups)
colon tumors and in HNPCC tumors and studied the
mechanisms underlying any abnormalities in these sub-
groups.
Methods
Patient material and tissue microarrays
Two tissue microarrays were constructed from formalin-
fixed, paraffin-embedded tissues as described previously
[24]. One array, previously described [25], included color-
ectal tumor specimens from 129 suspected HNPCC
patients with MSI-H colon tumors of which 75 cases were
analyzed in the present study after confirmation of their
HNPCC status: 73.3% (n = 55) of the latter possessed a
germline pathogenic mutation in hMLH1 (n = 24),
hMSH2 (n = 18), hMSH6 (n = 12) or PMS2 (n = 1), the
remaining were MSI-H, without methylation of the
hMLH1 promoter and/or with immunohistochemical loss
of the MSH2/MSH6 heterodimer and/or possessed a very
young age at diagnosis of colon cancer (<50 yrs old). All
cases possessed a positive family history for MSI-H
tumors. The second tissue array included 3 tumor tissue
cores from 81 sporadic right-sided colon cancer cases
resected between 1990 and 2005 at the Leiden University
Medical Center (Leiden, The Netherlands) and at the Rijn-
land Hospital (Leiderdorp, The Netherlands). The 81
patients in the latter array consisted of 47 females and 34
males with a mean age of 71.15 years (SD= 9.958).
Approximately 60% (n = 48) of these cases were classified
as MSS while the remaining (n = 33) possessed a MSI-H
phenotype. The microsatellite instability status of the
tumors was determined according to recommendations ofPage 2 of 11
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ver all MSI-H sporadic cases have lost the expression of the
MLH1/PMS2 heterodimer as assessed by immunohisto-
chemistry. The sporadic status of the MSI-H right-sided
tumors (RST) was confirmed by methylation analysis of
the hMLH1 promoter using a methylation-specific MLPA
assay as previously described [26]. All MSI-H sporadic
cases presented with hypermethylation at the hMLH1 pro-
moter.
The present study falls under approval by the Medical Eth-
ical Committee of the LUMC (protocol P01–019). Cases
were analyzed following the medical ethnical guidelines
described in the Code Proper Secondary Use of Human
Tissue established by the Dutch Federation of Medical Sci-
ences [27].
Immunohistochemistry
Standard three-step, indirect immunohistochemistry was
performed on 4-μm tissue sections transferred to glass
slides using a tape-transfer system (Instrumedics, Hacken-
sack, NJ), including citrate antigen retrieval, blockage of
endogenous peroxidase and endogenous avidin-binding
activity, and di-aminobenzidine development.
The following primary antibodies were used: the mAb
HCA2 which recognizes β2m-free HLA-A (except -A24), -
B7301 and -G heavy chains [28,29] ; the mAb HC10,
which recognizes a determinant expressed on all β2m-free
HLA-B and C heavy chains and on β2m-free HLA-A10, -
A28, -A29, -A30, -A31, -A32 and -A33 heavy chains
(supernatant kindly provided by Dr. J. Neefjes, NKI,
Amsterdam, The Netherlands and Dr. H. L. Ploegh, MIT,
Boston, MA) [28,30]; TAP1 specific mAb NOB1; LMP2-
specific mAb SY-1; LMP7-specific mAb HB2; LPM10-spe-
cific mAb TO-7; Calnexin-specific mAb TO-5; Calreticu-
lin-specific mAb TO-11; Tapasin-specific mAb TO-3;
ERp57-specific mAb TO-2 [31-33]; TAP2-specific mAb
(BD Biosciences Pharmingen, San Diego, CA); rabbit anti-
β2m polyclonal Ab (A 072; DAKO Cytomation, Glostrup,
Denmark); anti-MLH1 (clone G168–728; BD Bio-
sciences) and anti-PMS2 (clone A16-4; BD Biosciences).
Secondary reagents used were biotinylated rabbit anti-
mouse IgG antibodies (DAKO Cytomation), goat anti-
rabbit IgG antibodies (DAKO Cytomation), and bioti-
nylated-peroxidase streptavidin complex (SABC; DAKO
Cytomation).
Loss of expression was defined by complete lack of stain-
ing in membrane and cytoplasm (HCA2, HC10, and anti-
β2m), in the nucleus (anti-MLH1 and anti-PMS2), in the
peri-nucleus/endoplasmic reticulum (NOB1, anti-TAP2,
TO-2, TO-3, TO-5, TO-7, and TO-11), or in the cytoplasm
(SY-1, HB2, and TO-7), but with concurrent staining in
normal epithelium, stroma or infiltrating leukocytes. HLA
class I expression was considered to be lost when one of
the HLA class I antigen-specific antibodies gave a negative
result alongside a positive internal control (lymphocytic
infiltrate).
Flow cytometric sorting
The flow cytometric sorting procedure, including tissue
preparation, staining and flow cytometry analysis was per-
formed as described previously [34]. Briefly, 2 mm diam-
eter punches from selected areas of formalin-fixed
paraffin embedded colorectal carcinomas were digested
enzymatically in a mixture of 0.1% collagenase I-A
(Sigma-Aldrich, St Louis, MO, USA) and 0.1% dispase
(Gibco BRL, Paisley, UK). After determination of cell con-
centration, one million cells were incubated with 100 μl
of mAb mixture directed against keratin and vimentin
containing clones MNF116 (anti-keratin; IgG1; DAKOCy-
tomation, Golstrup, Denmark), AE1/AE3 (anti-keratin;
IgG1; Chemicon International Inc, Temecula, CA, USA),
and V9-2b (anti-vimentin; IgG2b; Department of Pathol-
ogy, LUMC [35]). Next day, cells were incubated with 100
μl of premixed FITC and RPE-labelled goat F(ab')2 anti-
mouse subclass-specific secondary reagents (Southern
Biotechnology Associates, Birmingham, AL, USA). After
washing, cells were incubated with 10 μM propidium
iodide (PI) and 0.1% DNase-free RNase (Sigma). The next
day cells were analyzed by flow cytometry. A standard
FACSCalibur (BD Biosciences) was used for the simulta-
neous measurement of FITC, RPE, and PI. Tumor and nor-
mal cell populations were flow-sorted using a
FACSVantage flow-sorter (BD Biosciences) using the FAC-
SCalibur filter settings. Sorting was only performed on
samples included in the RST array due to shortage of
material from the HNPCC cases. DNA from flow-sorted
tumor material was isolated as described by Jordanova et
al. [36]. DNA from non-sorted material was isolated using
Chelex extraction as described previously [37].
LOH and fragment analysis
Markers for loss of heterozygosity (LOH) analysis were
chosen from the dbMHC database [38] to map the chro-
mosome 6p21.3 region between HLA-A and TAP2. They
were MOGc, D6S510, C125, C141, D6S2444, TAP1 and
M2426. A "linker" sequence of 5'-GTTTCTT was added to
the 5' terminus of all reverse primers [39]. LOH was
defined as allelic imbalance >2 in the HNPCC cases (non-
sorted) and allelic imbalance >5 in the sorted RST [40].
To detect frame-shift mutations in the HLA-A, HLA-B,
β2m, LMP2, LMP7, LMP10, TAP1, TAP2, Calnexin, Calreti-
culin, ERp57 and Tapasin genes, 28 pairs of primers (Table
1) were constructed surrounding non-polymorphic mic-
rosatellite regions within the coding regions.Page 3 of 11
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Significance values were calculated using the software
package SPSS 10.0.7 (SPSS Inc., Chicago, IL, USA).
Results
HLA class I, β2m and APM component expression
In order to compare the expression of HLA class I in spo-
radic MSI-H and MSS right sided tumors (RST) and
HNPCC MSI-H cases, we used an antibody panel recog-
nizing monomorphic determinants expressed on HLA
class I heavy chains, β2m and APM components (Figure
1).
In total, we identified loss of HLA class I expression in
about 34.6% of the RST and 42.7% of the HNPCC cases.
The frequency of alterations differed significantly between
the sporadic MSS and MSI-H RST. The lack of HLA class I
expression was more frequent in MSI-H sporadic cases
than in MSS cases (p < 0.0001), as it was 16.7% in the lat-
ter group, but 60.6% in the former (Table 2).
Subsequently, we have investigated the frequency of a
concomitant loss of HLA class I expression with that of
either the β2m molecule or of any APM component. In
the sporadic subset, loss of HLA class I expression was
more often associated with that of one of the APM com-
ponents, occurring in about 37% of HLA-negative tumors
regardless of their mismatch repair status (Table 2). β2m
loss was only found in one HLA class I negative MSI-H
sporadic tumor (case 65) that interestingly also presented
loss of the APM molecules TAP2, Calreticulin and Tapasin
(Figure 2). In contrast, loss of HLA class I expression in
HNPCC cases was more frequently associated with that of
β2m (Table 2), as it was found in 46.9% of the HLA class
I-negative tumors. In contrast loss of any APM component
was observed in only 6% of these cases (h38, h49) which
also showed loss of β2m expression.
In sporadic RST, the simultaneous loss of more than one
APM molecule per case was frequent (Figure 2). Only 3
out of 10 cases lost a single APM component. The TAP2
molecule was most frequently lost (6 cases), followed by
TAP1, Tapasin and LMP2 (5 cases), Calreticulin (4 cases),
Table 1: Primers used in fragment analysis
Gene Forward primer Reverse primer Microsatellite Repeat
HLA A 4th ex CCTGAATTTTCTGACTCTTCCCGT GTTTCTTTCCCGCTGCCAGGTCAGTGT 7(C)
HLA A 5th ex CCATCGTGGGCATCATTG GTTTCTTTCAGTGAGACAAGAAATCTC 3(GGA)
HLA B 2nd ex GCTTCATCTCAGTGGGCTAC GTTTCTTCTCGCTCTGGTTGTA 3(GA) + 3(CA)
β2m 1st ex GGCTGGGCACGCGTTTAAT GTTTCTTAGGGAGAGAAGGACCAGAG 4(CT)
β2m 2nd ex (1) TACCCTGGCAATATTAATGTG GTTTCTTGATAGAAAGACCAGTCCTTGC 4(GA) + 5(A)
β2m 2nd ex (2) CTTACTGAAGAATGGAGAGAG GTTTCTTGACTACTCATACACAACTTTCA 5(A)
TAP1 1st ex TAAATGGCTGAGCTTCTCGC GTTTCTTAGAGCTAGCCATTGGCA 5(C)
TAP1 3rd ex ACAGCCACTTGCAGGGAG GTTTCTTTATGAACAGTACATGGCGTAT 5(T)
TAP1 8th ex CTGCCCTGCTGCAGAATCTG GTTTCTTCAAGCCACCTGCTTCCAT 5(G)
TAP1 10th ex CTCTGCAGAGGTAGACGAGG GTTTCTTATTAAGAAGATGACTGCCTCAC 5(G)
TAP1 11th ex AGCACCTCAGCCTGGTGGA GTTTCTTGCAGGTCTGAGAAGGCTTTC 6(G) + 5(A)
TAP2 2nd ex TTCCTCAAGGGCTGCCAGGAC GTTTCTTGCTCCAAGGGGCTGAAG 6(C)
TAP2 9th ex CCTACGTCCTGGTGAGGTGA GTTTCTTCTGGCTGTGCAGGTAGC 5(G)
Tapasin 2nd ex TTGGTTCGTGGAGGATGC GTTTCTTCCTAGAGACTCACCGTGTAC 5(G)
Tapasin 3rd ex CTTCCTTCTCTACACTCAGACC GTTTCTTAGGACTGGGCTGGATATGC 5(C)
Tapasin 4th ex CCTGTCTTCCTCAGTGGTAC GTTTCTTGAGCAGATGTCCCTTACCC 6(C)
Tapasin 5th ex TGCTCATTTCGTCCTCTTTCC GTTTCTTGTTCCCACTCCACCTCCAG 5(G)
Calnexin 7th ex GAAGGATCAGTTCCATGACAAG GTTTCTTCTGCATCTGGCCTCTTAGC 5(A)
Calnexin 8th ex TCTGCTCAATGACATGACTCC GTTTCTTTGAAGACAGTTCCCCAAGAC 5(A)
Calnexin 11th ex AACCTTTCAGAATGACTCCTTTTAG GTTTCTTCAAGCAGCAAACACGAACC 8(T)
Calreticulin 3rd ex CTACCGTCCCGTCTCAGG GTTTCTTTCTGTCTGGTCCAAACTATTAGG 5(G)
Calreticulin 6th ex GACAAGCCCGAGCATATCC GTTTCTTCACCTTGTACTCAGGGTTCTG 5(C)
ERp57 5th ex CACTTATTGCTTCTTCCTTGTG GTTTCTTAATACTTGGTCAGGAGATTCAAC 6(T)
ERp57 6th ex CTTCTGCTATCTGCCTACTGAG GTTTCTTTCAAGCAAATAAATCCCAGACAAG 6(A)
ERp57 13th ex ACTTTTAAGCTGATCTTTCTGTTTT GTTTCTTTTAGAGATCCTCCTGTGCCTT 6(C)
LMP2 2nd ex GAGGGCATCAAGGCTGTTC GTTTCTTGCAGACACTCGGGAATCAG 5(G)
LMP2 6th ex CCCTCTCTCCAACTTGAAACC GTTTCTTTGTAATAGTGACCAGGTAGATGAC 5(G)
LMP7 1st ex GGCTTTCGCTTTCACTTCC GTTTCTTGAGATCGCATAGAGAAACTGTAG 6(C)Page 4 of 11
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the LPM10 protein was detected in neither sporadic RST
nor HNPCC tumors. The HNPCC cases h38 and h49 lost
the expression of TAP2 and LMP7 respectively.
LOH and frameshift analysis
Polymorphic markers around the classical HLA genes (A,
B and C), TAP 1 and TAP2 genes were used to study LOH
and reveal possible chromosomal aberrations that could
Example of immunohistochemical analysis performed on the RST and HNPCC tumors (Amplification 10×)Figure 1
Example of immunohistochemical analysis performed on the RST and HNPCC tumors (Amplification 10×). A, Positive expres-
sion of HLA class I antigens detected with the HCA2 antibody. The epithelial (large arrow) membranous expression of HLA 
class I antigens is identical to the lymphocytic infiltrate (small arrow). B, Loss of expression of HLA class I identified with the 
HCA 2 antibody. The lymphocytic infiltrate (small arrow) was used as a positive control to determine the loss of expression on 
the epithelial cells. C, Loss of expression of β2m in a HNPCC case. D, Loss of expression of one of the APM members (Tapa-
sin) in a RST case.Page 5 of 11
(page number not for citation purposes)
BMC Cancer 2007, 7:33 http://www.biomedcentral.com/1471-2407/7/33relate to loss of HLA class I expression (Figure 5A). In
HNPCC cases, LOH analysis was only performed around
the HLA genes since loss of the TAP1 and TAP2 proteins
was rarely associated with HLA class I loss. LOH was more
frequent in the MSS tumors (50%) than in the MSI-H spo-
radic (20%) and HNPCC (6%) tumors with loss of HLA
class I expression (P < 0.05) (Figure 3, 4). Furthermore,
the patterns of LOH in the MSS cases might indicate loss
of the entire 6p21.3 region, in contrast to the MSI-H cases
(hereditary and sporadic forms) where LOH seems to be
limited.
Frameshift mutation screening of the microsatellite
sequences present in the coding regions of the HLA class
I, APM components and β2m genes was performed on all
cases with aberrant HLA class I expression (Figure 5B,C.
However specific genes were only analyzed when lack of
expression of the encoded proteins was detected by
immunohistochemistry. Of the classical HLA class I genes
only HLA-A and -B were analyzed since HLA-C does not
carry any microsatellite repeat in its coding region. Ten
RST cases and 20 HNPCC control cases with normal
expression of β2m and APM components were screened
for frameshift mutations and none was detected.
Frameshift mutations were mainly found in the MSI-H
cases (both sporadic and hereditary forms). At least one
mutation in an APM component gene was found in 6 of 7
sporadic MSI-H tumors that lost expression of one or
more APM components. The single sporadic MSI-H case
that lost β2m expression also presented with a single
frameshift mutation in the β2m gene. Of the 13 sporadic
MSI-H cases in which loss of HLA class I expression was
associated neither with APM component nor with β2m
loss as detected by immunohistochemical staining, one
presented with a frameshift in an HLA gene (case 39, Fig-
ure 3, Table 3) while 3 other cases showed LOH of the
markers adjacent the HLA genes (cases 7, 44 and 67). One
frameshift mutation was found in the Tapasin gene in a
MSS case (case 62). From 15 HNPCC tumors that lost
β2m expression at least one mutation was found in 8 cases
(Figure 4). Three of the latter showed 2 mutations local-
ized in different stretches. In the remaining 17 HNPCC
Table 2: HLA, APM and β2m expression in RST and HNPCC colon cancer
HLA† APM loss ‡ β2m loss ‡
RST
N = 81
MSS + 40 0 0
N = 48
(59,3%)
- 8 (16,7%) 3 (37,5%)* 0
MSI-H + 13 0 0
N = 33
(41,7%)
- 20 (60,6%) 7 (35,0%)* 1 (5,0%)*
HNPCC
N = 75
MSI-H + 43 0 0
- 32 (42,7%) 2 (6,3%)* 15 (46,9%)*
* – The percentage of cases that lost APM or β2m expression is relative to the number of HLA negative cases of each subset
† – HLA expression differs significantly between sporadic MSI-H and MSS tumors (p < 0.0001) and between HNPCC and sporadic MSS tumors (p < 
0.005)
‡ – The association of HLA class I loss with that of β2m and of APM components differs significantly (p < 0.0001) between sporadic RST and 
HNPCC tumors.
Loss of expression of β2m and different APM members was detected by immun histochemistry in the RST that pre-s nted with HLA lossFigur  2
Loss of expression of β2m and different APM members was 
detected by immunohistochemistry in the RST that pre-
sented with HLA loss. The shadowing (in black) is indicative 
for loss of expression of the respective molecules. (tpsn – 
Tapasin, calnx – Calnexin, crtcln – Calreticulin)Page 6 of 11
(page number not for citation purposes)
BMC Cancer 2007, 7:33 http://www.biomedcentral.com/1471-2407/7/33
Page 7 of 11
(page number not for citation purposes)
LOH and frameshift analysis was performed on sporadic RST that lost HLA class I expressionFigure 3
LOH and frameshift analysis was performed on sporadic RST that lost HLA class I expression. Only the tumors that presented 
with loss of one of the APM molecules or β2m were subjected to fragment analysis in their respective genes. The following 
repeats were analyzed for frameshift mutations: HLA A: 1 – 4th exon 7(C), 2 – 5th exon 3 (GGA); HLA – B: 3(GA) & 3(CA);β2m: 
1 – 1st exon 4(CT), 2 – 2nd exon 4(GA) & 5(A), 3 – 2nd exon 5(A); TAP1: 1 – 1st exon 5(C), 2 – 3rd exon 5(T), 3 – 8th exon 5(G), 
4 – 10th exon 5(G), 5 – 11th exon 6(G) & 5(A); TAP2: 1 – 2nd exon 6(C), 2 – 9th exon 5(G); Tapasin: 1 – 2nd exon 5(G), 2 – 3rd 
exon 5(C), 3 – 4th exon 6(C), 4 – 5th exon 5(G); Calnexin: 1 – 7th exon 5(A), 2 – 8th exon 5(A), 3 – 11th exon 8(T); Calreticulin: 1 
– 3rd exon 5(G), 6th exon 5(C); ERp57: 1 – 5th exon 6(T), 2 – 6th exon 6(A), 3 – 13th exon 6(C); LMP2: 1 – 2nd exon 5(G), 2 – 6th 
exon 5(G); LMP7: 1st exon 6(C) (key: ins – insertion; del – deletion; 0 – no mutation). LOH analysis of the 6p chromosome was 
also performed with the following markers: 1 – MOGc, 2 – D6S510, 3 – C125, 4 – C141, 5 – D6S2444, 6 – TAP1, 7 – M2426 
(Key: Black – Loss of heterozygosity; Striped – non informative marker; White – Retention of heterozygosity).
LOH and frameshift analysis was performed on HNPCC tumors that simultaneously lost HLA class I and β2m expressionFigure 4
LOH and frameshift analysis was performed on HNPCC tumors that simultaneously lost HLA class I and β2m expression. LOH 
markers: (see legend from Figure 3 for key). Frameshift markers:HLA A: 1 – 4th exon 7(C) 2 – 5th exon 3 (GGA); HLA – B: 3(GA) 
& 3(CA); β2m: 1 – 1st exon 4(CT), 2 – 2nd exon 4(GA). & 5(A), 3 – 2nd exon 5(A) (key: ins – insertion; del – deletion; 0 – no 
mutation; IHC -immunohistochemistry)
BMC Cancer 2007, 7:33 http://www.biomedcentral.com/1471-2407/7/33cases that solely lost HLA class I expression, only 4
showed genetic abnormalities. LOH was found in the
HLA region in cases h16, h56 and h120 (data not shown).
A frameshift mutation in one of the HLA genes (HLA B)
was found in one case (h99, Figure 4). In neither of the 2
HNPCC cases that immunohistochemically lost the
expression of one of the APM components an APM
frameshift mutation was found.
Discussion
Abnormalities in HLA class I cell surface expression are
commonly observed in tumors and are interpreted as a
mechanism by which tumor cells evade the host immune
system [1]. In colorectal cancer, especially in MSI-H
tumors, the high degree of lymphocytic infiltrate in some
cases may suggest an active immune response during
tumor development [41,42]. Moreover, MSI-H tumors
Table 3: Frameshift mutations description in RST
RST Mutation description
18 TAP2 (341–346)del1 – het
39 HLA-A (621–627)ins1 – het
65 β2m (341–345)del1 – hom; Tapasin (1217–1222)del1 – hom; Calreticulin 
(418–422)ins1 – hom
69 TAP1 (362–366)del1 – hom
78 ERp57 (675–680)del2 – hom; ERp57 (1459–1464)del1 – hom
90 HLA-A (621–627)ins1 – het; Calnexin (1476–1483)del1 – het
94 Tapasin (1217–1222)del1 – het
ins – insertion; del – deletion; hom – homozygous; het – heterozygous; the numbers before and after del/ins indicate the location of the 
microsatellite repeat containing the frameshift mutation and the number of affected nucleotides respectively.
Genetic analysis performed on tumors that have lost HLA class I expressionFigure 5
Genetic analysis performed on tumors that have lost HLA class I expression. The different peaks correspond to different sizes 
from the PCR-amplified products. Peaks corresponding to the normal samples are represented in green whereas tumor sam-
ples are represented in blue. A, LOH analysis performed on the RST 41 sample with the polymorphic marker C141. The total 
loss of a normal allele (on top) illustrates the technical advantage of using flow cytometric sorting to identify LOH events. B, 
Frameshift mutations identified in different members of the APM machinery. On top a homozygous deletion in the sample RST 
65 on the 4th exon of the Tapasin gene is shown. On the bottom, a heterozygous deletion in the sample RST 18 on the second 
exon of the TAP2 gene is shown. C, Frameshift mutation identified in one HNPCC case (h4) in the 2nd exon of the β2m gene. 
Because flow sorting was not performed in the HNPCC cases, we cannot determine whether the frameshifts are homo- or 
heterozygous due to contamination with normal DNA.Page 8 of 11
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quence of the high amounts of aberrant frameshift pep-
tides they generate [8,18]. A selective pressure by CTLs
upon these tumors would favor the outgrowth of tumor
cells that lost HLA class I expression at the cell surface
allowing them to surpass the action of the immune sys-
tem.
Applying immunohistochemistry on tissue arrays, we
compared HLA class I expression in both sporadic RST
(MSI-H and MSS sub-groups) and HNPCC tumors. RST
were chosen because of the high percentage of MSI-H
cases in this specific tumor type [43]. Indeed, immunohis-
tochemical staining with mAb showed that HLA class I
loss was frequent in the MSI-H cases analyzed when com-
pared to their MSS counterpart. This finding supports the
hypothesis that MSI-H tumors face greater selective pres-
sure to lose HLA class I expression, as described by Kloor
et al[8]. However, we have shown for the first time that
distinct molecular mechanisms underlie HLA class I loss
in sporadic MSI-H and HNPCC colon cancers. In the lat-
ter, HLA class I loss was preferentially associated with that
of β2m, while in the former HLA class I loss was associ-
ated with that of one or more APM components (p <
0.0001).
We investigated the genetic abnormalities underlying the
HLA class I loss of expression. They included LOH on
chromosome region 6p21.3 (encompassing HLA class I
and TAP genes), mutations in APM components and
mutations in β2m.
Loss of heterozygosity at 6p21.3 was most prevalent in
MSS tumors. This is consistent with the observation that
these tumors frequently possess gross chromosomal aber-
rations and are often aneuploid [13]. Moreover, since
LOH events in MSS tumors normally comprise large areas
of a chromosome, LOH on 6p21 might not be a direct
consequence of selective pressure directed to the loss of
HLA expression but instead to other genes within the
same chromosomal region. The general absence of LOH
in MSI-H tumors suggests that this is not the major mech-
anism by which the cells abrogate HLA class I expression.
The genome's coding regions contain multiple microsatel-
lite repeats, which are considered hotspots for mutations
in mismatch repair-deficient tumors [43]. Such repeats are
also present within the exons of the APM components,
β2m, HLA-A and HLA-B genes. In about half of the MSI-H
cases, loss of expression of HLA class I was concordant
with the detection of one or more mutations in these
genes. We have discovered novel mutations in the antigen
presenting machinery genes; Tapasin, Erp57, Calreticulin
and Calnexin in colorectal cancer. Previous reports associ-
ated the loss of HLA class I expression in MSI-H tumors
with defects on β2m molecule [7,9]. However, the authors
did not distinguish the sporadic/hereditary nature of the
tumors that were studied. We cannot exclude that the
MSI-H cases included in these studies were mainly
HNPCC tumors.
The reason sporadic MSI-H tumors would target APM
members for inactivation and HNPCC would target the
β2m chaperon is unclear. One possibility worth further
exploration is that the various mutations suggest different
immune-escape mechanisms for thwarting distinct anti-
tumor responses. HNPCC tumors can have an age of onset
before the 5th decade of life while sporadic MSI-H tumors
appear generally around the 7th decade of life [43]; one
would therefore predict that the alertness and robustness
of the immune system would be higher in HNPCC
patients leading to a stronger, or at least different selective
pressure on the latter. Furthermore it has been recently
suggested that the JC polyoma virus plays a role in the
oncogenicity of colon tumors with an identical phenotype
to sporadic MSI-H tumors [44]. Although speculative, the
presence of the JC virus might be implicated in a different
immune response between sporadic MSI-H and HNPCC
tumors.
The advantages of different escape mechanisms (loss of
APM members vs. abrogation of β2m) are not under-
stood. The only known function of APM members is facil-
itating the expression of HLA classical molecules in
complex with endogenous peptides. Thus, one would
expect that only these HLA molecules would be affected
by failure of the antigen processing machinery. On the
other hand, it is accepted that cell surface expression of
non-classical HLA molecules (e.g. HLA -G, -E) also
depends on β2m, so the function of these highly special-
ized molecules would be compromised if β2m were
mutated or lost. These molecules might play an important
role in regulation of immune cell activity by inhibiting or
activating its function. Therefore, MSI-H sporadic tumors
that have lost expression of both HLA and an APM com-
ponent and HNPCC tumors with lost β2m expression
might behave differently or present a different kind of
interaction with cells from the immune system. For
instance, Yamamoto et al. have described a correlation
between β2m mutations and unfavorable prognosis in
colorectal cancer [45].
We separately analyzed the presence of the characteristic
BRAF V600E somatic mutations in the RST cohort (data
not shown). Forty-percent of MSI-H sporadic tumors pre-
sented with this mutation which was absent in the MSS
tumors. It was previously described that this mutation is
also absent in HNPCC tumors [46]. V600E was distrib-
uted equally between tumors that lost vs. retained expres-
sion of HLA class I in the sporadic MSI-H cases.Page 9 of 11
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BMC Cancer 2007, 7:33 http://www.biomedcentral.com/1471-2407/7/33Conclusion
HLA class I aberrations are found at varying frequencies in
different colorectal tumor types and are caused by distinct
genetic mechanisms. Chiefly, sporadic and hereditary
MSI-H tumors follow different routes toward HLA class I
loss of expression supporting the idea that these tumors
follow different evolutionary pathways in tumorigenesis.
The resulting variation in immune escape mechanisms
may have repercussions in tumor progression and behav-
ior.
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